There are currently no FDA-approved medications for cocaine addiction. In the previous funding period, several animal models of cocaine abuse were used by this Center to investigate the neuropharmacology of chronic cocaine exposure. The studies described in Project 1 combine three research areas that were separated into distinct Projects in the previous version of the Center (formerly Projects 3, 5 and 6). These studies are designed to systematically investigate in monkeys and rats current medications used clinically to beat cocaine addiction, as well as drugs in the clinical """"""""pipeline"""""""" and drugs that are not approved for human use, but could provide information related to mechanisms of action related to clinical efficacy.
Specific Aim 1 will use rhesus monkeys self-administering cocaine to examine the effects of chronic administration of drugs. Treatment drugs that selective decrease cocaine- relative to food-reinforced responding, with no evidence of tolerance or attenuation by higher cocaine doses, will be evaluated in monkey models of cognition (Specific Aim 2). A positive outcome in models of cognition (i.e., improvement in performance) will yield additional studies in experimentally naive monkeys in combination with imaging studies (Projects 2 and 3). Finally, Specific Aim 3 will examine the effects of acute and chronic administration of drug treatments in several rat models of cocaine self-administration. When complete, the studies in this Project will provide basic science information in monkeys and rats across several behavioral endpoints in which different aspects of addiction are modeled, which should be of relevance to clinicians.
By combining a top-down approach, using drugs currently being evaluated clinically, with a mechanistic approach in several animal models of self-administration and cognition, areas of convergence will be identified that are relevant to identifying neuropharmacological mechanisms for effective treatment agents for cocaine addiction.
|Brodnik, Zachary D; Ferris, Mark John; Jones, Sara R et al. (2016) Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition. ACS Chem Neurosci :|
|Eldeeb, Khalil; Leone-Kabler, Sandra; Howlett, Allyn C (2016) CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function. J Basic Clin Physiol Pharmacol 27:311-22|
|Porrino, Linda J; Beveridge, Thomas J R; Smith, Hilary R et al. (2016) Functional consequences of cocaine expectation: findings in a non-human primate model of cocaine self-administration. Addict Biol 21:519-29|
|Karkhanis, Anushree N; Beveridge, Thomas J R; Blough, Bruce E et al. (2016) The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine. Drug Alcohol Depend 166:51-60|
|McGinnis, Molly M; Siciliano, Cody A; Jones, Sara R (2016) Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter. J Neurochem 138:821-9|
|Czoty, P W; Blough, B E; Fennell, T R et al. (2016) Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys. Neuroscience 324:367-76|
|Porrino, Linda J; Miller, Mack D; Smith, Hilary R et al. (2016) Neural Correlates of Exposure to Cocaine Cues in Rhesus Monkeys: Modulation by the Dopamine Transporter. Biol Psychiatry :|
|Siciliano, Cody A; Fordahl, Steve C; Jones, Sara R (2016) Cocaine Self-Administration Produces Long-Lasting Alterations in Dopamine Transporter Responses to Cocaine. J Neurosci 36:7807-16|
|Gould, R W; Czoty, P W; Porrino, L J et al. (2016) Social Status in Monkeys: Effects of Social Confrontation on Brain Function and Cocaine Self-Administration. Neuropsychopharmacology :|
|Brust, Tarsis F; Morgenweck, Jenny; Kim, Susy A et al. (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117|
Showing the most recent 10 out of 291 publications